INTRODUCTION: In this retrospective study, we compared motor disease progression in Ashkenazi-Jewish (AJ) Parkinson's disease (PD) patients carrying the LRRK2*G2019S mutation with that of noncarriers. METHODS: Consecutive PD patients were recruited between 2004 and 2011. Disease progression of carriers versus noncarriers was compared using survival analysis, where the end-point was the time from PD onset to reaching Hoehn and Yahr stage 3 (HY3). RESULTS: Overall, 405 AJ PD patients (males = 241[60%]) were genotyped, of whom 60 (males = 30) were LRRK2*G2019S mutation carriers. Time to HY3 did not differ significantly between mutation carriers and noncarriers (hazard ratio = 1.21, 95%CI = 0.83-1.77, P = 0.33). Age at PD onset was younger for carriers than for noncarriers (59.1 ± 9.8 vs. 63.2 ± 12.0 years, respectively; P = 0.005). In both groups, young age at onset was strongly associated with longer time to HY3, (P < 0.001). CONCLUSION: The LRRK2*G2019S mutation status has no discernible effect on the rate of motor disease progression in AJ PD patients.
INTRODUCTION: In this retrospective study, we compared motor disease progression in Ashkenazi-Jewish (AJ) Parkinson's disease (PD) patients carrying the LRRK2*G2019S mutation with that of noncarriers. METHODS: Consecutive PDpatients were recruited between 2004 and 2011. Disease progression of carriers versus noncarriers was compared using survival analysis, where the end-point was the time from PD onset to reaching Hoehn and Yahr stage 3 (HY3). RESULTS: Overall, 405 AJ PDpatients (males = 241[60%]) were genotyped, of whom 60 (males = 30) were LRRK2*G2019S mutation carriers. Time to HY3 did not differ significantly between mutation carriers and noncarriers (hazard ratio = 1.21, 95%CI = 0.83-1.77, P = 0.33). Age at PD onset was younger for carriers than for noncarriers (59.1 ± 9.8 vs. 63.2 ± 12.0 years, respectively; P = 0.005). In both groups, young age at onset was strongly associated with longer time to HY3, (P < 0.001). CONCLUSION: The LRRK2*G2019S mutation status has no discernible effect on the rate of motor disease progression in AJ PDpatients.
Authors: Rachel Saunders-Pullman; Anat Mirelman; Roy N Alcalay; Cuiling Wang; Roberto A Ortega; Deborah Raymond; Helen Mejia-Santana; Martha Orbe-Reilly; Brooke A Johannes; Avner Thaler; Laurie Ozelius; Avi Orr-Urtreger; Karen S Marder; Nir Giladi; Susan B Bressman Journal: JAMA Neurol Date: 2018-03-01 Impact factor: 18.302
Authors: Sindhu Srivatsal; Brenna Cholerton; James B Leverenz; Zbigniew K Wszolek; Ryan J Uitti; Dennis W Dickson; Daniel Weintraub; John Q Trojanowski; Vivianna M Van Deerlin; Joseph F Quinn; Kathryn A Chung; Amie L Peterson; Stewart A Factor; Cathy Wood-Siverio; Jennifer G Goldman; Glenn T Stebbins; Bryan Bernard; Beate Ritz; Rebecca Rausch; Alberto J Espay; Fredy J Revilla; Johnna Devoto; Liana S Rosenthal; Ted M Dawson; Marilyn S Albert; Ignacio F Mata; Shu-Ching Hu; Kathleen S Montine; Catherine Johnson; Thomas J Montine; Karen L Edwards; Jing Zhang; Cyrus P Zabetian Journal: Mov Disord Date: 2015-02-04 Impact factor: 10.338
Authors: Donald G Grosset; Michele Tao-Ming Hu; Michael Lawton; Manuela Mx Tan; Yoav Ben-Shlomo; Fahd Baig; Thomas Barber; Johannes C Klein; Samuel G Evetts; Stephanie Millin; Naveed Malek; Katherine Grosset; Roger A Barker; Nigel Williams; David J Burn; Thomas Foltynie; Huw R Morris; Nicholas Wood Journal: J Neurol Neurosurg Psychiatry Date: 2022-06-22 Impact factor: 13.654